

		Quarter Ended			Year Ended	
Sr. No.	Particulars	31 March	31 December	31 March	31 March	31 March
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		2018	2017	2017	2018	2017
1	Segment revenue					
	a. Pharmaceuticals	448	430	379	1790	1832
	b. Life Sciences Ingredients	95995	92953	75614	332511	260466
	Total	96443	93383	75993	334301	262298
	Less : Inter segment revenue				.	
	Total revenue from operations	96443	93383	75993	334301	262298
	a. Pharmaceuticals	448	430	379	1790	1832
	b. Life Sciences ingredients	95995	92953	75614	332511	260466
	Total	96443	93383	75993	334301	262298
2	Segment results {profit(+)/loss(-) before tax, exceptional items and Interest from each segment)					
	a Pharmaceuticals	(534)	(670)	(671)	(2746)	(2489)
	b. Life Sciences Ingredients	17323	19315	8996	55261	31465
	Total	16789	18645	8325	52515	28976
	Less : i Interest (Finance costs)	3275	3363	4283	13517	17425
	ii. Exceptional item and un-allocable expenditure (net of un-allocable income)	1636	959	1008	2229	99
	Profit before tax	11878	14323	3034	36769	11452
3	Segment assets					
	a. Pharmaceuticals	482	476	455	482	455
	b. Life Sciences Ingredients	271998	268687	237044	271998	237044
	c. Unallocable corporate assets (excluding deferred tax assets)	189974	191187	200680	189974	200680
	Total Segment assets	462454	460350	438179	462454	438179
4	Segment liabilities					
	a. Pharmaceuticals	856	747	661	856	661
	b. Life Sciences Ingredients	86194	77272	59489	86194	59489
	c. Unallocable corporate liabilities (excluding borrowings and deferred tax liabilities)	6078	8494	4908	6078	4908
	Total Segment liabilities	93128	86513	65058	93128	65058
5	Capital employed (Segment assets less Segment liabilities)					
	a Pharmaceuticals	(374)	(271)	(206)	(374)	(206)
	b. Life Sciences Ingredients	185804	191415	177555	185804	177555
	c. Unallocable corporate assets less liabilities	183896	182693	195772	183896	195772
	Total Capital employed	369326	373837	373121	369326	373121